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November 20111544 AbstractsConclusion: We hypothesized that a diagnosis of malignancy would
predispose patients to failure after peripheral endovascular intervention.
Surprisingly, patients with a history of malignancy showed equivalent pa-
tency to controls at 3 years post-intervention. To our knowledge, this is the
first study to show that the hypercoagulable state associated withmalignancy
is not an independent predictor of failure after peripheral endovascular
arterial intervention. Hence, a diagnosis of cancer should not preclude
endovascular interventions in symptomatic patients.
Hazard ratio
(95% Cl) P value
Primary patency
Diabetes mellitus 1.23 (1.06-1.43) .006
Chronic renal insufficiency 1.13 (.97-1.3) .097
Smoking 1.36 (1.11-1.67) .003
Critical limb Ischemia 2.28 (1.96-2.66) .001
Cancer .882 (.723-1.076) .215
Primary Assisted patency
Diabetes mellitus 1.35 (1.12-1.63) .002
Chronic renal insufficiency 1.29 (1.08-1.54) .004
Current Smoking 1.54 (1.21-1.96) .001
Critical limb Ischemia 3.52 (2.86-4.33) .001
Cancer .824 (.638-1.06) .135
Secondary patency
Diabetes mellitus 1.42 (1.15-1.76) .001
Chronic renel insufficiency 1.30 (1.07-1.58) .007
Current Smoking 1.58 (1.21-2.05) .001
Critical limb Ischemia 4.1 (3.2-5.3) .001
Cancer .837 (.633-1.10) .211
Limb Salvage
Diabetes mellitus 2.58 (1.48-4.48) .001
Chronic renal insufficiency 1.29 (.846-1.98) .234
Current Smoking 2.29 (1.38-3.81) .001
Cancer .706 (.355-1.40) .323
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Objectives: Intimal hyperplasia (IH) is defined as vascular smooth
muscle cell (VSMC) proliferation and is mediated by a number of cytokines
including TGF-. Our laboratory has previously demonstrated that TGF-’s
primary signaling pathway, Smad3, enhances VSMC proliferation and IH.
However, the exact mechanism by which Smad3 increases IH has yet to be
fully elucidated. We hypothesize that Smad3 mediates activation of ERK
MAPK through phosphorylation to increase VSMC proliferation thereby
increasing IH.
Methods:Cultured VSMC were infected with adenovirus expressing
Smad3 (AdSmad3) or control virus (AdGFP) and treated with TGF-.
VSMC were transfected with siRNA to Smad3 or scramble siRNA
(control) followed by stimulation with TGF-. Cell lysate was collected
for Western blot analysis or immunoprecipitation for proteins that com-
plex with Smad3 and immunoblotted by using p-ERK antibody. VSMC
were infected with AdSmad3 or AdGFP followed by pretreatment with
ERK inhibitor (PD 98059) then TGF-. Cell proliferation was deter-
mined by MTT assay. Male Sprague-Dawley rats underwent left carotid
balloon injury followed by intraluminal infection with AdSmad3 or
AdGFP. P-ERK and proliferating cell nuclear antigen (PCNA) were
evaluated by immunohistochemisty.
Results: TGF- increased expression of p-ERK at one hour in a
dose-dependent fashion.When compared to control-treated VSMC, TGF-
and Smad3 increased p-ERK expression by two-fold (p  0.05). Addition-
ally, siRNA to Smad3 decreased TGF--induced p-ERK expression by over
two-fold (p  0.05). The involvement of ERK in cell proliferation was
evaluated by pretreating VSMC with PD 98059 which decreased TGF-/
Smad3-induced cell proliferation by over two-fold (p 0.05). Immunopre-
cipitation demonstrated that Smad3 complexes with ERK in VSMC stimu-
lated with TGF-. In balloon-injured carotid arteries, treatment with
AdSmad3 (n  3) demonstrate enhanced p-ERK and PNCA when com-
pared to arteries treated with AdGFP (n  3, p  0.05).
Conclusions:We demonstrate that TGF--induced activation of ERK
is at least partially Smad3-dependent. We have shown that TGF-/Smad3
increases vascular smooth cell proliferation and this is mediated by ERK
MAPK activation. Inhibiting these components of the TGF-/Smad3 sig-
naling pathway may prevent the development of restenosis.
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iccelerated Aneurysmal Dilatation Associated with Apoptosis and
nflammation in a Newly Created Modified Calcium Chloride Rodent
AA Model
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Objective: The Calcium Chloride (CaCl2) model is a widely accepted
odent model for abdominal aortic aneurysm (AAA). Calcium deposition,
ainly consisting of calcium phosphate (CaPO4) crystals, has been reported
o exist in both human and experimental aneurysms. CaPO4 crystal has been
tilized for in vitro DNA transfection by mixing CaCl2 and Phosphate
uffered Saline (PBS). Here, we describe accelerated aneurysm formation
esulting from a modification of the CaCl2 model.
Methods: The modified CaCl2 model was created by applying PBS
nto the mouse infrarenal aorta after CaCl2 treatment. Morphological,
istological and immunohistochemical analysis were performed onmodified
aCl2 model and the conventional CaCl2 model as control. In vitro meth-
ds were carried out using a mixture of CaCl2 and PBS to create CaPO4
rystals. CaPO4 induced apoptosis of primary cultured mouse vascular
moothmuscle cells (VSMCs) wasmeasured byDNA fragmentation ELISA.
Results: First, we showed that the modified CaCl2 model produces
AA, defined as an increase of 50% or greater in the diameter of the aorta;
aster than in the CaCl2 model (Fig, A and B). Modified CaCl2 model
howed significantly larger aneurysmal dilation at 7, 28 and 42 days as
eflected by a maximum diameter fold change of 1.69  0.07, 1.99  0.14
nd 2.13  0.09 as opposed to 1.22  0.04, 1.48  0.07 and 1.68  0.06
s seen in CaCl2 model, respectively (n 6; P .05). Histological analyses
t 7 days reveal a significant increase in elastin degradation inmodifiedCaCl2
odel (Fig, C). Significantly higher level of apoptosis occurred in the
odified CaCl2 model (apoptosis index at 1, 2, and 3 days post-surgery:
.26  0.14, 0.37 0.14, and 0.33  0.08 for modified CaCl2 model and
.012 0.10, 0.15 0.02, and 0.12 0.05 for conventional CaCl2model)
n  3; P  .05). An enhancement of macrophage infiltration and calcifica-
ion was also observed at 3 and 7 days in modified CaCl2 model. CaPO4
nduced approximately 3.7 times more apoptosis in VSMCs when compared
o a mixture of CaCl2 and saline (n  4; P  .0001) in vitro.
Conclusion: Our data shows that the modified CaCl2 model acceler-
tes aneurysm formation with the enhancement of apoptosis, macrophage
nfiltration and calcium deposition. This modified model, with its rapid and
obust dilatation, can be utilized as a new model for AAA.
ndovascular Aortic Aneurysm Repair with Carbon Dioxide Guided
ngiography in Patients With Renal Insufficiency
nrique Criado, MD, Gilbert Upchurch, MD, John Rectenwald, MD, Kate
oung, RN, Dawn Coleman, MD, Jon Eliason, MD, Department of Sur-
ery, University of Michigan School of Medicine, Ann Arbor, Mich
Objectives: Renal dysfunction following endovascular abdominal aor-
ic aneurysm repair (EVAR) remains a source of morbidity andmortality.We
xamined the use of carbon dioxide (CO2) as a non-nephrotoxic contrast
gent for EVAR.
Methods: We analyzed prospectively recorded data from 114 consec-
tive patients who underwent EVARwith CO2 as the contrast agent over 44
Fig.onths. CO2 was used exclusively in 72 cases, and in 42, additional
odinated contrast (IC) was given (mean: 37 mLs.). Renal and hypogastric
